Barclays (LON:BARC) analyst Travis Steed maintained a Buy rating on Zimmer Biomet Holdings (NYSE:ZBH) on Friday, setting a price target of $178, which is approximately 25.65% above the present share price of $141.66.
Steed expects Zimmer Biomet Holdings to post earnings per share (EPS) of $0.68 for the fourth quarter of 2021.
The current consensus among 17 TipRanks analysts is for a Strong Buy rating of shares in Zimmer Biomet Holdings, with an average price target of $175.
The analysts price targets range from a high of $197 to a low of $140.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.03 billion and a net profit of $281.8 million. The company's market cap is $29.58 billion.
According to TipRanks.com, Barclays analyst Travis Steed is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 26.1% and a 65.79% success rate.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.